CA2159005C - Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules - Google Patents

Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules Download PDF

Info

Publication number: CA2159005C
Authority: CA; Canada
Prior art keywords: electroporation; cells; cell; red blood; chamber
Prior art date: 1993-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002159005A

Other languages

English (en)

Other versions

CA2159005A1 (fr

Inventor

Yves Claude Nicolau

Ulrich Bruggemann

Youssef Mouneimne

Eric Conrad Roux

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CBR Laboratories Inc

Original Assignee

CBR Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-23

Filing date

1994-03-23

Publication date

2007-06-19

1994-03-23 Application filed by CBR Laboratories Inc filed Critical CBR Laboratories Inc

1994-03-23 Priority claimed from PCT/US1994/003189 external-priority patent/WO1994021117A1/fr

1994-09-29 Publication of CA2159005A1 publication Critical patent/CA2159005A1/fr

2007-06-19 Application granted granted Critical

2007-06-19 Publication of CA2159005C publication Critical patent/CA2159005C/fr

2014-03-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 105
238000005538 encapsulation Methods 0.000 title abstract description 48
239000013543 active substance Substances 0.000 title abstract description 25
210000003743 erythrocyte Anatomy 0.000 claims abstract description 183
238000004520 electroporation Methods 0.000 claims abstract description 147
210000004027 cell Anatomy 0.000 claims abstract description 118
238000000926 separation method Methods 0.000 claims abstract description 30
229940088623 biologically active substance Drugs 0.000 claims abstract description 12
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical group OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 97
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 94
229940068041 phytic acid Drugs 0.000 claims description 94
238000001816 cooling Methods 0.000 claims description 52
238000011534 incubation Methods 0.000 claims description 14
238000005406 washing Methods 0.000 claims description 10
239000012530 fluid Substances 0.000 claims description 8
238000010438 heat treatment Methods 0.000 claims description 8
239000000306 component Substances 0.000 claims description 5
239000012503 blood component Substances 0.000 claims description 4
239000008280 blood Substances 0.000 abstract description 108
210000004369 blood Anatomy 0.000 abstract description 106
229910052760 oxygen Inorganic materials 0.000 abstract description 104
239000001301 oxygen Substances 0.000 abstract description 104
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 103
108010054147 Hemoglobins Proteins 0.000 abstract description 81
102000001554 Hemoglobins Human genes 0.000 abstract description 81
210000001519 tissue Anatomy 0.000 abstract description 30
239000012637 allosteric effector Substances 0.000 abstract description 22
210000002381 plasma Anatomy 0.000 abstract description 15
238000005215 recombination Methods 0.000 abstract 1
230000006798 recombination Effects 0.000 abstract 1
239000000725 suspension Substances 0.000 description 45
239000000243 solution Substances 0.000 description 32
239000002699 waste material Substances 0.000 description 26
230000008569 process Effects 0.000 description 23
239000006285 cell suspension Substances 0.000 description 15
230000000694 effects Effects 0.000 description 14
230000001965 increasing effect Effects 0.000 description 13
210000000170 cell membrane Anatomy 0.000 description 12
230000005684 electric field Effects 0.000 description 12
210000000265 leukocyte Anatomy 0.000 description 12
210000004072 lung Anatomy 0.000 description 12
230000036961 partial effect Effects 0.000 description 12
239000011148 porous material Substances 0.000 description 12
239000003146 anticoagulant agent Substances 0.000 description 11
229940127219 anticoagulant drug Drugs 0.000 description 11
230000027455 binding Effects 0.000 description 11
239000000872 buffer Substances 0.000 description 11
238000011109 contamination Methods 0.000 description 11
230000007423 decrease Effects 0.000 description 11
230000004083 survival effect Effects 0.000 description 11
238000011282 treatment Methods 0.000 description 10
238000010348 incorporation Methods 0.000 description 9
239000012528 membrane Substances 0.000 description 9
230000003204 osmotic effect Effects 0.000 description 9
238000006213 oxygenation reaction Methods 0.000 description 9
239000000047 product Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
230000003068 static effect Effects 0.000 description 8
238000001356 surgical procedure Methods 0.000 description 8
230000008901 benefit Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
201000010099 disease Diseases 0.000 description 7
239000011521 glass Substances 0.000 description 7
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
239000000203 mixture Substances 0.000 description 7
230000000717 retained effect Effects 0.000 description 7
229920006395 saturated elastomer Polymers 0.000 description 7
208000007502 anemia Diseases 0.000 description 6
210000000601 blood cell Anatomy 0.000 description 6
230000006870 function Effects 0.000 description 6
239000010931 gold Substances 0.000 description 6
229910052737 gold Inorganic materials 0.000 description 6
238000005534 hematocrit Methods 0.000 description 6
210000004180 plasmocyte Anatomy 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
239000004065 semiconductor Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
206010007559 Cardiac failure congestive Diseases 0.000 description 4
206010019280 Heart failures Diseases 0.000 description 4
108010064719 Oxyhemoglobins Proteins 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000009089 cytolysis Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
235000011180 diphosphates Nutrition 0.000 description 4
239000003792 electrolyte Substances 0.000 description 4
208000014674 injury Diseases 0.000 description 4
230000000302 ischemic effect Effects 0.000 description 4
239000002502 liposome Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
208000010125 myocardial infarction Diseases 0.000 description 4
-1 nucleotide triphosphates Chemical class 0.000 description 4
XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 3
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
206010022562 Intermittent claudication Diseases 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
229920000388 Polyphosphate Polymers 0.000 description 3
208000006011 Stroke Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
230000000747 cardiac effect Effects 0.000 description 3
230000006037 cell lysis Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000000151 deposition Methods 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
239000001177 diphosphate Substances 0.000 description 3
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
235000019797 dipotassium phosphate Nutrition 0.000 description 3
229910000396 dipotassium phosphate Inorganic materials 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
210000003617 erythrocyte membrane Anatomy 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000007789 gas Substances 0.000 description 3
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
229960000367 inositol Drugs 0.000 description 3
208000021156 intermittent vascular claudication Diseases 0.000 description 3
238000011068 loading method Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000035699 permeability Effects 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000001205 polyphosphate Substances 0.000 description 3
235000011176 polyphosphates Nutrition 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
208000007056 sickle cell anemia Diseases 0.000 description 3
230000008961 swelling Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000008736 traumatic injury Effects 0.000 description 3
239000011534 wash buffer Substances 0.000 description 3
INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000000919 ceramic Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
239000012809 cooling fluid Substances 0.000 description 2
239000000112 cooling gas Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000010586 diagram Methods 0.000 description 2
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
150000003278 haem Chemical class 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000004001 inositols Chemical class 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
230000002934 lysing effect Effects 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000013021 overheating Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
229920000447 polyanionic polymer Polymers 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000000287 tissue oxygenation Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
208000005223 Alkalosis Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
239000000592 Artificial Cell Substances 0.000 description 1
229910001152 Bi alloy Inorganic materials 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010015287 Erythropenia Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000036581 Haemorrhagic anaemia Diseases 0.000 description 1
108010085682 Hemoglobin A Proteins 0.000 description 1
102000007513 Hemoglobin A Human genes 0.000 description 1
208000032456 Hemorrhagic Shock Diseases 0.000 description 1
206010021113 Hypothermia Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
CTPQAXVNYGZUAJ-UHFFFAOYSA-N Inositol pentaphosphate Natural products OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O CTPQAXVNYGZUAJ-UHFFFAOYSA-N 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027423 Metabolic alkalosis Diseases 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
229910001245 Sb alloy Inorganic materials 0.000 description 1
229910001370 Se alloy Inorganic materials 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229910001215 Te alloy Inorganic materials 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
CTPQAXVNYGZUAJ-UYSNGIAKSA-N [(1s,2r,4s,5r)-3-hydroxy-2,4,5,6-tetraphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O CTPQAXVNYGZUAJ-UYSNGIAKSA-N 0.000 description 1
YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000037328 acute stress Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003012 bilayer membrane Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000005796 circulatory shock Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000009146 cooperative binding Effects 0.000 description 1
208000029039 cyanide poisoning Diseases 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
108010002255 deoxyhemoglobin Proteins 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
238000010292 electrical insulation Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
108010036302 hemoglobin AS Proteins 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
239000000815 hypotonic solution Substances 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229910001412 inorganic anion Inorganic materials 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000011810 insulating material Substances 0.000 description 1
210000005061 intracellular organelle Anatomy 0.000 description 1
UETZVSHORCDDTH-UHFFFAOYSA-N iron(2+);hexacyanide Chemical compound [Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] UETZVSHORCDDTH-UHFFFAOYSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
239000005060 rubber Substances 0.000 description 1
239000011669 selenium Substances 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
235000019832 sodium triphosphate Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000012414 sterilization procedure Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
230000009424 thromboembolic effect Effects 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
- A61M1/3696—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/02—Electrical or electromagnetic means, e.g. for electroporation or for cell fusion
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0429—Red blood cells; Erythrocytes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Hematology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Sustainable Development (AREA)
Anesthesiology (AREA)
Virology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Botany (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Electromagnetism (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002159005A 1993-03-23 1994-03-23 Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules Expired - Lifetime CA2159005C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3546793A	1993-03-23	1993-03-23
US035,467		1993-03-23
PCT/US1994/003189 WO1994021117A1 (fr)	1993-03-23	1994-03-23	Methode et appareil d'encapsulation de substances biologiquement actives dans des cellules

Publications (2)

Publication Number	Publication Date
CA2159005A1 CA2159005A1 (fr)	1994-09-29
CA2159005C true CA2159005C (fr)	2007-06-19

Family

ID=38281389

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002159005A Expired - Lifetime CA2159005C (fr)	1993-03-23	1994-03-23	Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules

Country Status (1)

Country	Link
CA (1)	CA2159005C (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20190382706A1 (en) *	2017-02-27	2019-12-19	Koji Tanabe	Somatic cell production system
WO2020123649A1 (fr) *	2018-12-11	2020-06-18	Lonza Walkersville, Inc.	Système et procédés d'ingénierie cellulaire automatisés de chevet
SG11202106030QA (en) *	2018-12-11	2021-07-29	Lonza Walkersville Inc	Cell isolation for use in automated bioreactors

1994
- 1994-03-23 CA CA002159005A patent/CA2159005C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2159005A1 (fr)	1994-09-29

Legal Events

Date	Code	Title	Description
1999-02-19	EEER	Examination request
2014-05-26	MKEX	Expiry	Effective date: 20140324

Publication	Publication Date	Title
EP0690671B1 (fr)	2004-08-04	Methode et appareil d'encapsulation de substances biologiquement actives dans des cellules
US5720921A (en)	1998-02-24	Flow electroporation chamber and method
US6074605A (en)	2000-06-13	Flow electroporation chamber and method
US6617154B1 (en)	2003-09-09	Electroporation chamber including an electrode having a continuous, crystalline metal nitride coating
CA2214800C (fr)	2002-01-22	Chambre d'electroporation en flux et procede associe
US6773669B1 (en)	2004-08-10	Flow electroporation chamber and method
US4652449A (en)	1987-03-24	Encapsulating biological active substances into erythrocytes
EP2277594B1 (fr)	2016-03-30	Procédé et dispositif de lyse-rescellement pour l'incorporation de principe actif dans des érythrocytes
US20010001064A1 (en)	2001-05-10	Flow electroporation chamber and methods of use thereof
EP1456345A2 (fr)	2004-09-15	Appareil et procede d'electroporation d'echantillons biologiques
CA2159005C (fr)	2007-06-19	Methode et appareillage pour l'encapsulation de substances biologiquement actives dans les cellules
AU754218B2 (en)	2002-11-07	Flow electroporation chamber and method
CA2363548A1 (fr)	1996-09-19	Chambre d'electroporation en flux et procede associe
HK1016096A (en)	1999-10-29	Flow electroporation chamber and method
HK1110030B (en)	2013-03-28	Lysis/resealing process and device for incorporating an active ingredient in erythrocytes